AstraZeneca PLC vs Banco Bilbao Vizcaya Argentaria, S.A.: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and Banco Bilbao Vizcaya Argentaria, S.A. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating Banco Bilbao Vizcaya Argentaria, S.A., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and Banco Bilbao Vizcaya Argentaria, S.A. is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $58.7B against ~$41.7B for Banco Bilbao Vizcaya Argentaria, S.A., while their respective market capitalizations stand at $254.6B and $139.7B. AstraZeneca PLC is headquartered in United Kingdom and Banco Bilbao Vizcaya Argentaria, S.A. in Spain, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA is a Spanish banking group that earns more abroad than at home. It is Spain's second-largest bank, but Mexico produced ~$5.95B (EUR5.264B) of its ~$11.9B (EUR10.511B) net attributable profit in 2025, with Turkey, Colombia, Peru, Argentina, Uruguay and a corporate and investment banking arm making up the rest. The group employed 127,174 people at the end of 2025 and served 81.2 million active customers.

AstraZeneca PLC and Banco Bilbao Vizcaya Argentaria, S.A. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and Banco Bilbao Vizcaya Argentaria, S.A..

AstraZeneca PLC business model: AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

Banco Bilbao Vizcaya Argentaria, S.A. business model: BBVA runs a universal banking model built on local subsidiaries that fund themselves with local deposits, so a shock in one country does not drain the parent. Customer deposits reached ~$568B (EUR502.5B) at the end of 2025 against ~$534B (EUR472.7B) of gross loans, and net interest income of ~$29.7B (EUR26.280B) provided about 71 percent of gross income. Fees from payments, cards, asset management and insurance added ~$9.28B (EUR8.215B) and net trading income ~$3B (EUR2.656B). Distribution is mostly digital: 81.2 million active customers were served through 5,642 branches and 31,015 ATMs, and the efficiency ratio of 38.8 percent is one of the lowest among large European banks.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of Banco Bilbao Vizcaya Argentaria, S.A..

AstraZeneca PLC competitive advantage: AstraZeneca's main advantage is the depth of its oncology portfolio and the Phase III evidence behind it. Tagrisso, Imfinzi, Enhertu, Lynparza and Calquence each rest on trials that changed treatment practice, and the company had more than 100 Phase III studies running at the end of 2025 after 16 positive Phase III readouts during the year. Scale matters too: $58.7 billion of Total Revenue and $14.2 billion of annual R&D spending let it fund late-stage trials that smaller biotechs cannot, which is why partners such as Daiichi Sankyo and Amgen co-develop medicines with it. Its commercial reach in emerging markets, where China alone is about 12% of revenue, is wider than that of most US-based rivals.

Banco Bilbao Vizcaya Argentaria, S.A. competitive advantage: BBVA's first advantage is scale in Mexico, where BBVA Mexico is the largest bank in the country and produced ~$5.95B (EUR5.264B) of net attributable profit in 2025, close to half the group total. The second is cost: operating expenses grew 1.0 percent in euros in 2025 while gross income grew 4.1 percent, holding the efficiency ratio at 38.8 percent with a branch network trimmed to 5,642 offices. Group ROTE of 19.3 percent is a level BBVA describes as leading among large European banks.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and Banco Bilbao Vizcaya Argentaria, S.A. each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

Banco Bilbao Vizcaya Argentaria, S.A. growth strategy: After the Banco Sabadell offer lapsed in October 2025, BBVA's growth plan rests on organic lending, digital expansion in Europe and capital returns. Loans and advances to customers grew 11.5 percent in 2025 and customer funds 13.5 percent. The group opened a branch-free digital bank in Italy in October 2021, which passed 800,000 customers by its fourth anniversary and targets one million during 2026, and launched a second digital bank in Germany in June 2025. Capital released by the 2021 transfer of BBVA USA to PNC still underpins buybacks and dividends, with half of 2025 profit earmarked for shareholders.

A closer look at the financial trajectory of AstraZeneca PLC and Banco Bilbao Vizcaya Argentaria, S.A. rounds out the comparison.

AstraZeneca PLC: AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA's profit is spread across five business areas. In 2025 Spain contributed ~$4.72B (EUR4.175B) of net attributable profit, Mexico ~$5.95B (EUR5.264B), Turkey ~$910M (EUR805M), South America ~$820M (EUR726M) and Rest of Business ~$709M (EUR627M), while the Corporate Center recorded a ~$1.23B (EUR1.086B) loss. Gross income rose 4.1 percent in reported euros but 16.3 percent at constant exchange rates, the gap being mostly the weaker Mexican peso. Loan-loss impairments were ~$6.86B (EUR6.073B) with a cost of risk of 1.39 percent, and the NPL ratio improved to 2.7 percent with 85 percent coverage. CET1 capital closed at 12.70 percent against a 9.28 percent requirement, and BBVA set total 2025 shareholder distributions at 50 percent of profit, EUR0.92 per share in cash.